Mallinckrodt; Eure Meinung zur Bewertung. (Seite 6)
eröffnet am 22.09.17 12:52:21 von
neuester Beitrag 27.07.23 15:12:32 von
neuester Beitrag 27.07.23 15:12:32 von
Beiträge: 58
ID: 1.262.472
ID: 1.262.472
Aufrufe heute: 0
Gesamt: 9.868
Gesamt: 9.868
Aktive User: 0
ISIN: IE00BBGT3753 · WKN: A1W0TN
0,6369
EUR
0,00 %
0,0000 EUR
Letzter Kurs 13.10.20 Tradegate
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 0,6080 | +26,25 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,6000 | -12,16 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
NEWS PROVIDED BY
Mallinckrodt plc
Jan 30, 2018, 16:45 ET
SHARE THIS ARTICLE
STAINES-UPON-THAMES, United Kingdom, Jan. 30, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Acthar Gel as a therapy option in patients with pulmonary sarcoidosis.
H.P. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the respiratory condition symptomatic sarcoidosis, one of 19 indications.
"I am pleased that the first patient has been enrolled in this important Phase 4 study, the results of which may potentially provide evidence to further support Acthar as a treatment option in appropriate symptomatic sarcoidosis patients," said Dr. Robert Baughman, M.D., Professor in the Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio1. "In my experience, a considerable number of sarcoidosis patients can have persistent disease that may not be resolved by first-line treatment."
"The enrollment of the first patient in this study is an important milestone in our further assessment of Acthar's efficacy as a treatment option for sarcoidosis patients," said Tunde Otulana, M.D., Chief Medical Officer at Mallinckrodt. "We believe this exploratory evaluation of the more challenging patients who may still have disease activity after previous therapies can potentially help physicians better understand which individuals may benefit from the drug as a treatment alternative."
Full study details can be found on clinicaltrials.gov.
About the Trial
The Phase 4 clinical study is titled "Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis." This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of H.P. Acthar Gel in the treatment of pulmonary sarcoidosis. All subjects who meet eligibility criteria – which include a requirement to be receiving prednisone treatment – will be randomly assigned to receive either 1mL (80 units) of H.P. Acthar Gel or 1mL of a matching placebo subcutaneously 2 times/week. Subjects will be assigned to treatment in a 1:1 ratio with up to 50 subjects per arm for a total of up to 100 subjects. Subjects who complete the 24-week randomized, double-blind, placebo-controlled treatment period will be eligible to continue in an optional 24-week open-label extension.
Response will be evaluated by Sarcoidosis Treatment Score (STS) with a time frame of baseline to 24 weeks. STS is an exploratory newly developed composite score that combines the results of pulmonary function tests (forced vital capacity; diffusing capacity of the lungs for carbon monoxide), high-resolution computed tomography, quality of life (King's Sarcoidosis Questionnaire; Fatigue Assessment Scale) and corticosteroid tapering.
Find more information about the trial here on the ClinicalTrials.gov website.
About Symptomatic Sarcoidosis2,3,4
Sarcoidosis is a challenging, yet treatable, rare multisystem disease. In some cases the symptoms may come and go throughout a lifetime. This is referred to as symptomatic sarcoidosis. In people with sarcoidosis the immune system overreacts, forming clumps of cells called granulomas that result in inflammation to the body's tissues. The disease can impact any organ, but it most often impacts the lungs, lymph nodes, eyes, and skin. Over 90 percent of people with sarcoidosis will suffer lung problems. Concomitant involvement of organs outside of the lungs is common, occurring in as many as half of all sarcoidosis cases.
About H.P. Acthar Gel (repository corticotropin injection)
Indications
H.P. Acthar Gel is an injectable drug approved by the FDA for the treatment of 19 indications. Of these, today the majority of Acthar use is in these indications:
Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
The treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
The treatment of symptomatic sarcoidosis
Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Treatment of severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation
IMPORTANT SAFETY INFORMATION
Contraindications
Acthar should never be administered intravenously
Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
Acthar is contraindicated where congenital infections are suspected in infants
Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins
Warnings and Precautions
The adverse effects of Acthar are related primarily to its steroidogenic effects
Acthar may increase susceptibility to new infection or reactivation of latent infections
Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Adverse Reactions
Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve
Other adverse events reported are included in the full Prescribing Information.
Please see full Prescribing Information.
For parents and caregivers of IS patients, please also see Medication Guide.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
Mallinckrodt, the "M" brandmark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2018 ARDUS/01-13/0118/0002 01/18
1 Dr. Baughman's association with Mallinckrodt includes research grants support, consulting, and involvement with the speakers' bureau.
2 Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allerg Immunol. 2015;49:63-78.
3 Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573-581.
4 Shigemitsu H, Patel HV, Schreiber MP. Extrapulmonary sarcoidosis. In: Judson MA, ed. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician. Vol 17. New York, NY: Springer Science+Business Media; 2014:149-186.
SOURCE Mallinckrodt plc
Related Links
http://www.mallinckrodt.com
NEWS PROVIDED BY
Mallinckrodt plc
Jan 30, 2018, 16:45 ET
SHARE THIS ARTICLE
STAINES-UPON-THAMES, United Kingdom, Jan. 30, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Acthar Gel as a therapy option in patients with pulmonary sarcoidosis.
H.P. Acthar Gel is approved by the U.S. Food and Drug Administration (FDA) for the respiratory condition symptomatic sarcoidosis, one of 19 indications.
"I am pleased that the first patient has been enrolled in this important Phase 4 study, the results of which may potentially provide evidence to further support Acthar as a treatment option in appropriate symptomatic sarcoidosis patients," said Dr. Robert Baughman, M.D., Professor in the Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio1. "In my experience, a considerable number of sarcoidosis patients can have persistent disease that may not be resolved by first-line treatment."
"The enrollment of the first patient in this study is an important milestone in our further assessment of Acthar's efficacy as a treatment option for sarcoidosis patients," said Tunde Otulana, M.D., Chief Medical Officer at Mallinckrodt. "We believe this exploratory evaluation of the more challenging patients who may still have disease activity after previous therapies can potentially help physicians better understand which individuals may benefit from the drug as a treatment alternative."
Full study details can be found on clinicaltrials.gov.
About the Trial
The Phase 4 clinical study is titled "Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis." This is a Phase 4, multicenter, randomized, double-blind, placebo-controlled pilot study evaluating the efficacy and safety of H.P. Acthar Gel in the treatment of pulmonary sarcoidosis. All subjects who meet eligibility criteria – which include a requirement to be receiving prednisone treatment – will be randomly assigned to receive either 1mL (80 units) of H.P. Acthar Gel or 1mL of a matching placebo subcutaneously 2 times/week. Subjects will be assigned to treatment in a 1:1 ratio with up to 50 subjects per arm for a total of up to 100 subjects. Subjects who complete the 24-week randomized, double-blind, placebo-controlled treatment period will be eligible to continue in an optional 24-week open-label extension.
Response will be evaluated by Sarcoidosis Treatment Score (STS) with a time frame of baseline to 24 weeks. STS is an exploratory newly developed composite score that combines the results of pulmonary function tests (forced vital capacity; diffusing capacity of the lungs for carbon monoxide), high-resolution computed tomography, quality of life (King's Sarcoidosis Questionnaire; Fatigue Assessment Scale) and corticosteroid tapering.
Find more information about the trial here on the ClinicalTrials.gov website.
About Symptomatic Sarcoidosis2,3,4
Sarcoidosis is a challenging, yet treatable, rare multisystem disease. In some cases the symptoms may come and go throughout a lifetime. This is referred to as symptomatic sarcoidosis. In people with sarcoidosis the immune system overreacts, forming clumps of cells called granulomas that result in inflammation to the body's tissues. The disease can impact any organ, but it most often impacts the lungs, lymph nodes, eyes, and skin. Over 90 percent of people with sarcoidosis will suffer lung problems. Concomitant involvement of organs outside of the lungs is common, occurring in as many as half of all sarcoidosis cases.
About H.P. Acthar Gel (repository corticotropin injection)
Indications
H.P. Acthar Gel is an injectable drug approved by the FDA for the treatment of 19 indications. Of these, today the majority of Acthar use is in these indications:
Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
The treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
The treatment of symptomatic sarcoidosis
Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Treatment of severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation
IMPORTANT SAFETY INFORMATION
Contraindications
Acthar should never be administered intravenously
Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
Acthar is contraindicated where congenital infections are suspected in infants
Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins
Warnings and Precautions
The adverse effects of Acthar are related primarily to its steroidogenic effects
Acthar may increase susceptibility to new infection or reactivation of latent infections
Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
Cushing's syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Adverse Reactions
Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve
Other adverse events reported are included in the full Prescribing Information.
Please see full Prescribing Information.
For parents and caregivers of IS patients, please also see Medication Guide.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
Mallinckrodt, the "M" brandmark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2018 ARDUS/01-13/0118/0002 01/18
1 Dr. Baughman's association with Mallinckrodt includes research grants support, consulting, and involvement with the speakers' bureau.
2 Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allerg Immunol. 2015;49:63-78.
3 Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573-581.
4 Shigemitsu H, Patel HV, Schreiber MP. Extrapulmonary sarcoidosis. In: Judson MA, ed. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician. Vol 17. New York, NY: Springer Science+Business Media; 2014:149-186.
SOURCE Mallinckrodt plc
Related Links
http://www.mallinckrodt.com
Antwort auf Beitrag Nr.: 56.130.083 von Zimtzicke am 08.11.17 11:51:29..passte schon 
Antwort auf Beitrag Nr.: 56.130.083 von Zimtzicke am 08.11.17 11:51:29
Umsatzrückgang war minimal stärker als erwartet.
In den 3 Quartalen 2017 wurden laut finanzen.net.
Ein eps von 4,19 verdient.
Vom eps und Gewinnmargen ein klarer Kauf. Aber viel Goodwill in der Bilanz. Der Goodwill wird derzeit bei fallenden Aktienkursen gerne abgeschrieben. Das verringert das Eigenkapital und die Eigenkapitalquote.
Es wurde kein Ausblick gegeben.
Gewinn fehlt.
Es wurde ein Gewinn eps für Q3 von 1,824 USD erwartet. Es wurde nur ein Gewinn eps von 0,66 USD erzielt.Umsatzrückgang war minimal stärker als erwartet.
In den 3 Quartalen 2017 wurden laut finanzen.net.
Ein eps von 4,19 verdient.
Vom eps und Gewinnmargen ein klarer Kauf. Aber viel Goodwill in der Bilanz. Der Goodwill wird derzeit bei fallenden Aktienkursen gerne abgeschrieben. Das verringert das Eigenkapital und die Eigenkapitalquote.
Es wurde kein Ausblick gegeben.
....Kurse für einen Einstieg ??!!
Quartalszahlen
Mallinckrodt PLC Quartalszahlen 07.11.17 Trading Spotlight
Antwort auf Beitrag Nr.: 55.803.096 von Boersenfreund9 am 22.09.17 16:12:41
Die Ertragszahlen sehen sehr gut aus. Aus der Vergangenheit wie auch prognostiziert für die Zukunft.
Der Umsatz steigt auch.
Aber ordentlich Goodwill in der Bilianz.
Kennt jemand den Grund warum die Aktie so abrauscht.
Die Ertragszahlen sehen sehr gut aus. Aus der Vergangenheit wie auch prognostiziert für die Zukunft.
Der Umsatz steigt auch.
Aber ordentlich Goodwill in der Bilianz.
Kennt jemand den Grund warum die Aktie so abrauscht.
Mallinckrodt Pharmaceuticals-Aktie leicht im Plus
Dienstag, 13.06.2017 16:03 von ARIVA.DE
Die Aktie von Mallinckrodt Pharmaceuticals (Mallinckrodt Pharmaceuticals Aktie) notiert am Dienstag ein wenig fester. Die Aktie notiert zur Stunde bei 43,26 US-Dollar.
Für das Wertpapier von Mallinckrodt Pharmaceuticals steht gegenwärtig ein Preisanstieg 4,27 Prozent zu Buche. Das Wertpapier verteuerte sich um 1,77 US-Dollar. Am Aktienmarkt zahlen private und institutionelle Anleger derzeit 43,26 US-Dollar für das Papier. Der Anteilsschein von Mallinckrodt Pharmaceuticals steht aufgrund dieser Entwicklung immer noch besser da als der Gesamtmarkt, gemessen am S&P 500. Der S&P 500 notiert gegenwärtig bei 2.436 Punkten. Das entspricht lediglich einem Plus von 0,22 Prozent gegenüber der letzten Notierung des vorigen Handelstages.
Mallinckrodt plc. ist ein biopharmazeutischer Konzern, der Spezialprodukte und Medikamente entwickelt, fertigt und vertreibt. Darüber hinaus ist das Unternehmen in der Weiterentwicklung medizinischer Bildgebungsverfahren tätig. Im vergangenen Geschäftsjahr erwirtschaftete Mallinckrodt Pharmaceuticals unter dem Strich einen Gewinn von 644 Mio. US-Dollar. Der Umsatz belief sich auf 3,38 Mrd. US-Dollar. Am 8. Mai 2017 lässt sich Mallinckrodt Pharmaceuticals erneut in die Bücher schauen. Dann werden die neuesten Geschäftszahlen veröffentlicht.
Dieser Artikel wurde von ARIVA.DE mithilfe von Unternehmensinformationen von Finance Base standardisiert erstellt.
Dienstag, 13.06.2017 16:03 von ARIVA.DE
Die Aktie von Mallinckrodt Pharmaceuticals (Mallinckrodt Pharmaceuticals Aktie) notiert am Dienstag ein wenig fester. Die Aktie notiert zur Stunde bei 43,26 US-Dollar.
Für das Wertpapier von Mallinckrodt Pharmaceuticals steht gegenwärtig ein Preisanstieg 4,27 Prozent zu Buche. Das Wertpapier verteuerte sich um 1,77 US-Dollar. Am Aktienmarkt zahlen private und institutionelle Anleger derzeit 43,26 US-Dollar für das Papier. Der Anteilsschein von Mallinckrodt Pharmaceuticals steht aufgrund dieser Entwicklung immer noch besser da als der Gesamtmarkt, gemessen am S&P 500. Der S&P 500 notiert gegenwärtig bei 2.436 Punkten. Das entspricht lediglich einem Plus von 0,22 Prozent gegenüber der letzten Notierung des vorigen Handelstages.
Mallinckrodt plc. ist ein biopharmazeutischer Konzern, der Spezialprodukte und Medikamente entwickelt, fertigt und vertreibt. Darüber hinaus ist das Unternehmen in der Weiterentwicklung medizinischer Bildgebungsverfahren tätig. Im vergangenen Geschäftsjahr erwirtschaftete Mallinckrodt Pharmaceuticals unter dem Strich einen Gewinn von 644 Mio. US-Dollar. Der Umsatz belief sich auf 3,38 Mrd. US-Dollar. Am 8. Mai 2017 lässt sich Mallinckrodt Pharmaceuticals erneut in die Bücher schauen. Dann werden die neuesten Geschäftszahlen veröffentlicht.
Dieser Artikel wurde von ARIVA.DE mithilfe von Unternehmensinformationen von Finance Base standardisiert erstellt.
Ich habe jetzt gerade die Aktie ganz oberflächlich Überflogen.
Was meint Ihr dazu?
Dabei bin ich auf folgenden Bericht gestoßen. Nun ist der Aktienkurs nach viel weiter gefallen....
Wenn nichts dazwischen gekommen ist sollte die Bewertung nach niedriger sein....
MALLINCKRODT – Ein Jahr Bodenbildung
19.12.16, 19:34 GodmodeTrader
Mallinckrodt PLC - WKN: A1W0TN - ISIN: IE00BBGT3753 - Kurs: 50,285 € (Frankfurt)
Mallinckrodt plc. ist ein biopharmazeutischer Konzern, der Spezialprodukte und Medikamente entwickelt, fertigt und vertreibt. Darüber hinaus ist das Unternehmen in der Weiterentwicklung medizinischer Bildgebungsverfahren tätig. Der Fokus der Unternehmenstätigkeit liegt auf der Erforschung therapeutischer Medikamente und Schmerzmittel.
Seit dem Spin-Off von Covidien 2011 hat sich der Wert im Hoch verdreifacht. Doch der Großteil dieser Rally wurde im vergangenen Jahr wieder eingestampft. Seitdem bildet der Wert einen Boden aus und wir seitdem immer wider zwischen 51,75 und 56,60 USD aufgefangen.
Fundamental erscheint das Unternehmen nach den massiven Verlusten erstaunlich attraktiv bewertet zu sein. Die forward P/E liegt bei 7 nach aktuell 12,3. Der Buchwert liegt mit 49,12 USD nahe am Aktienkurs. Der Umsatz konnte seit der Abspaltung von 2,0 auf inzwischen über 3,3 Mrd USD gesteigert werden. Der Gewinn je Aktie legte im selben Zeitraum von 2,61 auf 5,77 USD je Aktie zu.
Wie bereits angesprochen, wird der Wert seit Monaten im Bereich zwischen 51,75 und 56,60 USD akkumuliert, das Rückschlagpotenzial scheint bei der hohen Profitabilität und dem vorliegenden Buchwert eher gering. Ausgehend vom aktuellen Niveau könnte es zügig wieder in Richtung 56,60 USD gehen. Darüber kommt es zu einem Kaufsignal mit möglichen Kurszielen bei 60,00 und 68,25 USD.
Haben Sie Interesse an täglichen Hot Stocks, einem langfristigen Investment-Depot und jederzeit über 300 frei zugängliche Chartanalysen? Schauen Sie doch auf meinem Guidants-Desktop vorbei.
Mallinckrodt PLC
Schon im Weihnachtsfieber? Dann haben wir gute Neuigkeiten! Die Türchen unseres GodmodeTrader-Adventkalenders sind bereits geöffnet und viele Rabatten und Aktionen warten auf Sie. Machen Sie sich selbst eine vorweihnachtliche Freude und entdecken Sie jetzt, was sich der Weihnachtsmann für Sie ausgedacht hat. Warten Sie nicht zu lange - denn täglich schließt sich ein Türchen nach dem anderen! Hier geht’s zum Adventskalender.
(© BörseGo AG 2016 - Autor: Tobias Krieg, Technischer Analyst)
Was meint Ihr dazu?
Dabei bin ich auf folgenden Bericht gestoßen. Nun ist der Aktienkurs nach viel weiter gefallen....
Wenn nichts dazwischen gekommen ist sollte die Bewertung nach niedriger sein....
MALLINCKRODT – Ein Jahr Bodenbildung
19.12.16, 19:34 GodmodeTrader
Mallinckrodt PLC - WKN: A1W0TN - ISIN: IE00BBGT3753 - Kurs: 50,285 € (Frankfurt)
Mallinckrodt plc. ist ein biopharmazeutischer Konzern, der Spezialprodukte und Medikamente entwickelt, fertigt und vertreibt. Darüber hinaus ist das Unternehmen in der Weiterentwicklung medizinischer Bildgebungsverfahren tätig. Der Fokus der Unternehmenstätigkeit liegt auf der Erforschung therapeutischer Medikamente und Schmerzmittel.
Seit dem Spin-Off von Covidien 2011 hat sich der Wert im Hoch verdreifacht. Doch der Großteil dieser Rally wurde im vergangenen Jahr wieder eingestampft. Seitdem bildet der Wert einen Boden aus und wir seitdem immer wider zwischen 51,75 und 56,60 USD aufgefangen.
Fundamental erscheint das Unternehmen nach den massiven Verlusten erstaunlich attraktiv bewertet zu sein. Die forward P/E liegt bei 7 nach aktuell 12,3. Der Buchwert liegt mit 49,12 USD nahe am Aktienkurs. Der Umsatz konnte seit der Abspaltung von 2,0 auf inzwischen über 3,3 Mrd USD gesteigert werden. Der Gewinn je Aktie legte im selben Zeitraum von 2,61 auf 5,77 USD je Aktie zu.
Wie bereits angesprochen, wird der Wert seit Monaten im Bereich zwischen 51,75 und 56,60 USD akkumuliert, das Rückschlagpotenzial scheint bei der hohen Profitabilität und dem vorliegenden Buchwert eher gering. Ausgehend vom aktuellen Niveau könnte es zügig wieder in Richtung 56,60 USD gehen. Darüber kommt es zu einem Kaufsignal mit möglichen Kurszielen bei 60,00 und 68,25 USD.
Haben Sie Interesse an täglichen Hot Stocks, einem langfristigen Investment-Depot und jederzeit über 300 frei zugängliche Chartanalysen? Schauen Sie doch auf meinem Guidants-Desktop vorbei.
Mallinckrodt PLC
Schon im Weihnachtsfieber? Dann haben wir gute Neuigkeiten! Die Türchen unseres GodmodeTrader-Adventkalenders sind bereits geöffnet und viele Rabatten und Aktionen warten auf Sie. Machen Sie sich selbst eine vorweihnachtliche Freude und entdecken Sie jetzt, was sich der Weihnachtsmann für Sie ausgedacht hat. Warten Sie nicht zu lange - denn täglich schließt sich ein Türchen nach dem anderen! Hier geht’s zum Adventskalender.
(© BörseGo AG 2016 - Autor: Tobias Krieg, Technischer Analyst)
Durchsuchen
